Browse by author
Lookup NU author(s): Emeritus Professor Andrew MellorORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Tumors actively suppress antitumor immunity, creating formidable barriers to successful cancer immunotherapy. The molecular mechanisms underlying tumor-induced immune tolerance are largely unknown. In the present study, we show that dendritic cells (DC) in the tumor microenvironment acquire the ability to metabolize vitamin A to produce retinoic acid (RA), which drives regulatory T-cell responses and immune tolerance. Tolerogenic responses were dependent on induction of vitamin A-metabolizing enzymes via the β-catenin/T-cell factor (TCF) pathway in DCs. Consistent with this observation, DC-specific deletion of β-catenin in mice markedly reduced regulatory T-cell responses and delayed melanoma growth. Pharmacologic inhibition of either vitamin A-metabolizing enzymes or the β-catenin/TCF4 pathway in vivo had similar effects on tumor growth and regulatory T-cell responses. Hence, β-catenin/TCF4 signaling induces local regulatory DC and regulatory T-cell phenotypes via the RA pathway, identifying this pathway as an important target for anticancer immunotherapy.
Author(s): Hong Y, Manoharan I, Suryawanshi A, Majunder T, Angus-Hill A, Koni PA, Manicassamy B, Mellor AL, Munn DH, Manicassamy S
Publication type: Article
Publication status: Published
Journal: Cancer Research
Year: 2015
Volume: 75
Issue: 4
Pages: 656-665
Print publication date: 15/02/2015
Online publication date: 07/01/2015
Acceptance date: 26/11/2014
ISSN (print): 0008-5472
ISSN (electronic): 1538-7445
Publisher: American Association for Cancer Research
URL: http://dx.doi.org/10.1158/0008-5472.CAN-14-2377
DOI: 10.1158/0008-5472.CAN-14-2377
PubMed id: 25568183
Altmetrics provided by Altmetric
